- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Dana Rathkopf addresses the complex challenge of managing prostate cancer patients who show low-volume disease on conventional imaging but high-volume disease on next-generation PET imaging. The presentation explores evidence suggesting PET-only metastases may be more indolent than conventional imaging-visible disease. Biographies:...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Christopher Sweeney discusses strategies for managing early progression after combination therapy in prostate cancer. He emphasizes the importance of proper patient and tumor profiling while presenting ENZAMET trial data showing survival differences based on progression patterns. Biographies: Christopher Sweeney, MBBS, Professor of...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Maria De Santis presents an overview of managing frail patients with metastatic hormone-sensitive prostate cancer. The presentation explores treatment efficacy data and challenges in frail patients, while emphasizing the importance of supportive interventions and individualized treatment approaches. Biographies: Maria De Santis, MD...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Gerhardt Attard discusses the future landscape of prostate cancer treatments and biomarkers, introducing STAMPEDE2's multi-arm trial design. Dr. Attard also addresses key challenges in radiographic progression-free survival measurements, patient selection, and treatment sequencing. Biographies: Gerhardt Attard, MD, PhD, FRCP, John...
|
- Details
- Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer. The conversation explores validation studies demonstrating the test's prognostic value for overall survival and its potential to predict benefit from metastasis-directed therapy using data from the STOMP and ORIOLE trials. The...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Silke Gillessen joins Neeraj Agarwal to discuss the results of the STAMPEDE trial's metformin arm. The phase 3 trial evaluates the addition of metformin to androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer. While the primary endpoint of overall survival is not met, the study reveals significant improvements in metabolic parameters, including reduced w...
|
- Details
- Phillip Koo and Zachary Klaassen discuss the UpFrontPSMA study, a Phase 2 trial published in Lancet Oncology. The study evaluates lutetium-177 PSMA-617 followed by docetaxel versus docetaxel alone in patients with de novo high-volume metastatic hormone-sensitive prostate cancer. They highlight the trial design, which uses PSMA and FDG PET for patient selection, and discuss key results. The primary...
|
- Details
- Zachary Klaassen hosts Sarah Howlett and Mahaz Kayani about the STAMPEDE2 platform trial, focusing on Arm N, which tests niraparib-abiraterone in metastatic hormone-sensitive prostate cancer patients with specific homologous recombination repair gene alterations. They discuss the trial's design, which randomizes patients to receive either a dual-action tablet of niraparib-abiraterone or standard A...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the ARANOTE trial, a phase III study evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's design, which randomized 669 patients to darolutamide plus ADT or placebo plus ADT. The study meets its primary endpoint, showing significant improvement in radiographic progression-free survival for the darolutami...
|